ETF Holdings Breakdown of ORIC

News associated with ORIC

Tower Research Capital LLC TRC Purchases 13,384 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)

Tower Research Capital LLC TRC lifted its position in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Free Report) by 1,048.1% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 14,661 shares of the company’s stock after purchasing an additional 13,384 shares during the quarter. […] - 2025-05-09 08:21:00

MetLife Investment Management LLC Purchases 5,530 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)

MetLife Investment Management LLC grew its position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Free Report) by 15.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 41,608 shares of the company’s stock after acquiring an additional 5,530 shares during the period. MetLife Investment […] - 2025-05-07 08:28:51

HC Wainwright Reiterates Buy Rating for ORIC Pharmaceuticals (NASDAQ:ORIC)

ORIC Pharmaceuticals (NASDAQ:ORIC – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They currently have a $21.00 price target on the stock. HC Wainwright’s price target suggests a potential upside of 316.67% from the stock’s previous close. Other analysts […] - 2025-05-07 05:58:49

XTX Topco Ltd Has $210,000 Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)

XTX Topco Ltd increased its holdings in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Free Report) by 120.9% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 25,966 shares of the company’s stock after acquiring an additional 14,209 shares during the period. XTX […] - 2025-04-28 08:11:12

Brokerages Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) PT at $18.86

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) has received a consensus recommendation of “Buy” from the nine brokerages that are currently covering the company, Marketbeat reports. Nine research analysts have rated the stock with a buy recommendation. The average 12 month price target among brokerages that have covered the stock in the last year […] - 2025-04-25 05:32:47

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Acquired by Wellington Management Group LLP

Wellington Management Group LLP increased its holdings in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Free Report) by 6.9% during the fourth quarter, HoldingsChannel reports. The fund owned 186,430 shares of the company’s stock after buying an additional 12,042 shares during the period. Wellington Management Group LLP’s holdings in ORIC Pharmaceuticals were worth $1,504,000 at […] - 2025-04-14 07:45:06

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives $18.86 Consensus PT from Brokerages

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) has been assigned an average rating of “Buy” from the nine research firms that are covering the stock, MarketBeat Ratings reports. Nine equities research analysts have rated the stock with a buy recommendation. The average 1 year target price among analysts that have covered the stock in […] - 2025-03-31 05:32:43

ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up Following Better-Than-Expected Earnings

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) shares gapped up prior to trading on Wednesday following a better than expected earnings announcement. The stock had previously closed at $7.85, but opened at $8.57. ORIC Pharmaceuticals shares last traded at $7.99, with a volume of 78,926 shares traded. The company reported ($0.51) EPS for the […] - 2025-02-21 06:56:45

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Average Rating of “Buy” from Analysts

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) has received an average recommendation of “Buy” from the nine research firms that are presently covering the stock, MarketBeat.com reports. Nine research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among analysts that have issued a report on the stock in […] - 2025-02-11 08:30:52

ORIC institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-05-08	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	33,897	USD 180,332
2025-05-08	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	33,897	USD 180,332 11.7%
2025-05-08	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	14,062	USD 74,810 11.7%
2025-05-08	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	445	USD 2,367
Total =		82,301	USD 437,841

Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer